11.08.20at, Bioengineered Skin Substitutes

By 09/15/2026 (15 days before effective date): Billing team must immediately update billing system, fee schedules, and claim submission software to reflect coverage status changes. CRITICAL ACTIONS: (1) Flag and deny all claims for HCPCS codes A2046, A2047, A2048, A2049, A2050, Q4207, Q4223, Q4243 submitted after 10/01/2026 as experimental/investigational unless documented as meeting approved indications. (2) Update system edits for revised codes A2040, A2041, A2042, A2043, A2045, Q4298, Q4299 per Attachment A specifications. (3) Change effective date to 01/01/2026 for G-codes G0681, G0682, G0683, G0684 in billing system and apply retroactively to any claims submitted between 01/01/2026-10/01/2026. (4) Providers must document all five criteria for chronic lower extremity wounds including wound size ≥1.0 cm², clean granular base without tendon/muscle/bone involvement, absence of infection, adequate circulation (ABI ≥0.60 or toe pressure >30 mm Hg), and failed response to conservative care (4+ weeks for general wounds or diabetic ulcers with neuropathy; 3+ months for venous ulcers unresponsive for 30+ days). (5) Update encounter forms and EMR templates to capture required documentation. (6) Train billing staff that claims lacking this documentation will be denied. (7) Communicate to providers that acute wounds, post-Mohs procedures, and post-surgical uses are now explicitly experimental/investigational and will not be covered. Failure to implement these changes will result in claim denials, revenue loss, and potential compliance violations.